Supplemental Table 1. Semiquantitative immuno-PET data for the 4 cohorts.

	Tumor SUV_{max}		MBP SUV_{mean}		Tumor-to-MBP ratio	
Cohorts	60 min	120 min	60 min	120 min	60 min	120 min
I (TF2 120/24h/IMP 6/20)						
Patient 1	-	3.52	-	0.79	-	4.46
Patient 2	7.55	6.38	4.58	1.78	1.65	3.58
Patient 3	27.89	26.38	2.48	2.13	11.25	12.38
Max	27.89	26.38	4.58	2.13	11.25	12.38
Min	7.55	3.52	2.48	0.79	1.65	3.58
Median	17.72	6.38	3.53	1.78	6.45	4.46
II (TF2 120/30h/IMP 6/20)						
Patient 4	8.53	7.72	1.59	1.42	5.36	5.44
Patient 5	6.96	9.53	4.69	3.88	1.48	2.46
Patient 7	5.24	4.59	1.80	1.23	2.91	3.73
Patient 18	23.83	34.44	3.84	2.34	6.21	14.72
Patient 21a	44.05	47.89	0.80	0.59	55.06	81.17
Patient 21b	71.05	65.04	2.26	2.13	31.44	30.54
Patient 22	28.14	34.21	6.39	4.70	4.40	7.28
Patient 23	6.01	10.24	7.07	6.09	0.85	1.68
Max	71.05	65.04	7.07	6.09	55.06	81.17
Min	5.24	4.59	0.80	0.59	0.85	1.68
Median	16.18	22.23	3.05	2.24	4.88	6.36
III (TF2 120/30h/IMP 3/40)						
Patient 8	5.89	6.89	6.16	5.60	0.96	1.23
Patient 9	11.34	21.80	0.74	0.36	15.32	60.56
Patient 11	56.99	61.57	1.87	1.20	30.48	51.31
Patient 12	19.14	25.24	3.60	2.69	5.32	9.38
Patient 19a	22.41	14.62	0.60	0.74	37.35	19.76
Patient 19b	16.07	17.60	0.72	0.91	22.32	19.34
Patient 20	15.10	14.68	0.62	0.28	24.35	52.43
Max	22.41	61.57	6.16	5.60	37.35	60.56
Min	5.89	6.89	0.60	0.28	0.96	1.23
Median	16.07	17.60	0.74	0.91	22.32	19.76
IV (TF2 60/30h/IMP 3/20)						
Patient 13	8.22	12.07	1.64	0.91	5.01	13.26
Patient 15	28.24	28.74	4.56	1.3	6.19	22.12
Patient 16	8.98	8.27	1.72	0.94	5.22	8.80
Patient 17	19.13	16.34	3.77	1.82	5.07	8.98
Max	28.24	28.74	4.56	1.82	6.19	22.12
Min	8.22	8.27	1.64	0.91	5.01	8.80
Median	14.06	14.21	2.75	1.12	5.15	11.12

MBP: Mediastinal Blood Pool; (TF2 dose nmol/Delay/^{68}Ga-IMP288 nmol/molar dose ratio).